This company listing is no longer active
Otonomy Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
11.1%
Tasa de crecimiento de los beneficios
28.4%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 7.3% |
| Tasa de crecimiento de los ingresos | -48.0% |
| Rentabilidad financiera | -244.2% |
| Margen neto | n/a |
| Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Otonomy. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -52 | 14 | 35 |
| 30 Jun 22 | 0 | -53 | 14 | 37 |
| 31 Mar 22 | 0 | -53 | 14 | 36 |
| 31 Dec 21 | 0 | -51 | 15 | 35 |
| 30 Sep 21 | 0 | -48 | 15 | 31 |
| 30 Jun 21 | 0 | -46 | 15 | 29 |
| 31 Mar 21 | 0 | -45 | 15 | 28 |
| 31 Dec 20 | 0 | -45 | 15 | 28 |
| 30 Sep 20 | 0 | -45 | 15 | 29 |
| 30 Jun 20 | 0 | -44 | 13 | 30 |
| 31 Mar 20 | 1 | -44 | 12 | 32 |
| 31 Dec 19 | 1 | -45 | 12 | 33 |
| 30 Sep 19 | 1 | -47 | 13 | 35 |
| 30 Jun 19 | 1 | -49 | 16 | 36 |
| 31 Mar 19 | 1 | -51 | 19 | 35 |
| 31 Dec 18 | 1 | -50 | 20 | 32 |
| 30 Sep 18 | 1 | -56 | 22 | 28 |
| 30 Jun 18 | 1 | -65 | 28 | 31 |
| 31 Mar 18 | 1 | -74 | 34 | 35 |
| 31 Dec 17 | 1 | -90 | 43 | 43 |
| 30 Sep 17 | 1 | -98 | 48 | 51 |
| 30 Jun 17 | 1 | -104 | 49 | 55 |
| 31 Mar 17 | 1 | -111 | 51 | 59 |
| 31 Dec 16 | 1 | -111 | 50 | 60 |
| 30 Sep 16 | 0 | -105 | 45 | 59 |
| 30 Jun 16 | 0 | -94 | 40 | 53 |
Ingresos de calidad: 7OT is currently unprofitable.
Margen de beneficios creciente: 7OT is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 7OT is unprofitable, but has reduced losses over the past 5 years at a rate of 11.1% per year.
Acelerando crecimiento: Unable to compare 7OT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 7OT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.1%).
Rentabilidad financiera
Alta ROE: 7OT has a negative Return on Equity (-244.24%), as it is currently unprofitable.